Stockscreener 앱 받기
10.94
7.68%
0.78
시장 영업 전:
11.03
0.09
+0.82%
전일 마감가:
$10.16
열려 있는:
$10.3
하루 거래량:
722.29K
Relative Volume:
0.58
시가총액:
$646.29M
수익:
-
순이익/손실:
$-153.16M
주가수익비율:
-2.9648
EPS:
-3.69
순현금흐름:
$-134.48M
1주 성능:
+5.70%
1개월 성능:
+3.31%
6개월 성능:
+47.44%
1년 성능:
-5.36%
1일 변동 폭
$10.24
$11.35
1주일 범위
$9.41
$11.35
52주 변동 폭
$5.68
$13.33
쿨리난 온콜로지 Stock (CGEM) Company Profile
명칭
Cullinan Therapeutics Inc
전화
617-410-4650
주소
ONE MAIN STREET, CAMBRIDGE
CGEM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
10.94 | 600.21M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
쿨리난 온콜로지 Stock (CGEM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-21 | 재개 | H.C. Wainwright | Buy |
| 2025-06-11 | 재개 | Stifel | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-05-01 | 개시 | Stifel | Buy |
| 2024-04-15 | 개시 | William Blair | Outperform |
| 2024-02-15 | 개시 | Wedbush | Outperform |
| 2023-06-15 | 개시 | TD Cowen | Outperform |
| 2022-11-21 | 개시 | BTIG Research | Buy |
| 2021-04-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | 개시 | Evercore ISI | Outperform |
| 2021-02-02 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-02-02 | 개시 | SVB Leerink | Outperform |
| 2021-02-01 | 개시 | H.C. Wainwright | Buy |
모두보기
쿨리난 온콜로지 주식(CGEM)의 최신 뉴스
Cullinan Therapeutics (NASDAQ:CGEM) Shares Up 9.5%Here's Why - MarketBeat
Cullinan Therapeutics, Inc.Common Stock (NQ:CGEM) - FinancialContent
Oncology Drugs Fast-Tracked by the FDA in December 2025 - Oncology News Central
Cullinan Therapeutics (NASDAQ:CGEM) Trading Up 3.9%What's Next? - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Nadim Ahmed Sells 9,922 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Assenagon Asset Management S.A. Has $1.05 Million Stake in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics (CGEM) price target increased by 19.75% to 32.84 - MSN
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap DownTime to Sell? - MarketBeat
Insider Sell: Jennifer Michaelson Sells Shares of Cullinan Thera - GuruFocus
Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $13,463.45 in Stock - MarketBeat
Cullinan Therapeutics CSO Sells Shares - TradingView — Track All Markets
Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $28,023.66 in Stock - Defense World
Cullinan Therapeutics (CGEM) Price Target Increased by 19.75% to 32.84 - Nasdaq
Will Cullinan Therapeutics Inc. stock deliver shareholder value2025 Price Targets & Weekly High Potential Stock Alerts - ulpravda.ru
Cullinan Therapeutics price target raised to $34 from $25 at Wedbush - MSN
Cullinan Therapeutics Earnings Notes - Trefis
Cullinan Therapeutics shows rising price performance with jump to 93 RS rating - MSN
Is Cullinan Therapeutics Inc. stock a contrarian buy2025 Fundamental Recap & Free Real-Time Market Sentiment Alerts - Улправда
Jacquelyn Sumer Sells 3,480 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Jeffrey Alan Jones Sells 4,632 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Cullinan Therapeutics Executives Sell Shares for Tax Obligations - TradingView — Track All Markets
Officer Michaelson Files To Sell 1,345 Of Cullinan Therapeutics Inc [CGEM] - TradingView — Track All Markets
How Cullinan Therapeutics Inc. stock reacts to inflationary pressures2025 Sector Review & Reliable Intraday Trade Plans - Улправда
Jobs Data: Will Cullinan Therapeutics Inc. stock deliver better than expected guidanceMarket Trend Summary & Technical Buy Zone Confirmations - Улправда
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Cullinan Management (CGEM) - The Globe and Mail
Will Cullinan Therapeutics (NASDAQ:CGEM) Spend Its Cash Wisely? - Yahoo Finance
Cowen reiterates Buy rating on Cullinan Oncology stock after ASH data - Investing.com Nigeria
Cullinan Therapeutics (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 2,148 Shares of Stock - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 995 Shares - MarketBeat
Cullinan Therapeutics (CGEM) Jumps on Promising Phase 1 Data for CLN-049 in AML, Showing Strong Response Rates - Finviz
Cullinan Therapeutics presents promising CLN-049 data - MSN
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 9.5%What's Next? - MarketBeat
20 Stocks That Will Double in 2026 - Insider Monkey
Cullinan Therapeutics, Inc. (CGEM) Presents at The 67th American Society of Hematology (ASH) Annual MeetingSlideshow (NASDAQ:CGEM) 2025-12-11 - Seeking Alpha
Weekly Research Analysts’ Ratings Updates for Cullinan Therapeutics (CGEM) - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $34.00 at Wedbush - Defense World
Wedbush Maintains Cullinan Therapeutics (CGEM) Outperform Recommendation - Nasdaq
Holdings of Cullinan Therapeutics Inc (CGEM) are aligned with the stars - setenews.com
Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $34.00 - MarketBeat
Wedbush Raises Price Target on CGEM to $34, Maintains Outperform - GuruFocus
CGEM: CLN-049 demonstrates strong efficacy and safety in AML, advancing toward pivotal trials - TradingView — Track All Markets
Cullinan Therapeutics (NASDAQ:CGEM) Trading 9.3% HigherWhat's Next? - MarketBeat
Cullinan Oncology stock soars after promising AML treatment results By Investing.com - Investing.com Canada
Cullinan’s leukemia drug shows promising results in clinical trial By Investing.com - Investing.com South Africa
Cullinan Therapeutics Presents Promising CLN-049 Data - TipRanks
Cullinan Therapeutics (CGEM) Reveals Encouraging Phase 1 Data fo - GuruFocus
Cullinan’s leukemia drug shows promising results in clinical trial - Investing.com
Cullinan Therapeutics Reports Promising Phase 1 Data for CLN-049 in Patients with Relapsed/Refractory AML, Receives FDA Fast Track Designation - Quiver Quantitative
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting - GlobeNewswire
쿨리난 온콜로지 (CGEM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
28.63%
자본화:
|
볼륨(24시간):